BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34296279)

  • 1. Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeutics.
    Akimov SS; Jiang M; Kedaigle AJ; Arbez N; Marque LO; Eddings CR; Ranum PT; Whelan E; Tang A; Wang R; DeVine LR; Talbot CC; Cole RN; Ratovitski T; Davidson BL; Fraenkel E; Ross CA
    Hum Mol Genet; 2021 Nov; 30(24):2469-2487. PubMed ID: 34296279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.
    Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H
    Mol Brain; 2012 May; 5():17. PubMed ID: 22613578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.
    Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J
    Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes.
    HD iPSC Consortium
    Cell Stem Cell; 2012 Aug; 11(2):264-78. PubMed ID: 22748968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progerin-Induced Transcriptional Changes in Huntington's Disease Human Pluripotent Stem Cell-Derived Neurons.
    Cohen-Carmon D; Sorek M; Lerner V; Divya MS; Nissim-Rafinia M; Yarom Y; Meshorer E
    Mol Neurobiol; 2020 Mar; 57(3):1768-1777. PubMed ID: 31834602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling Huntington's disease with induced pluripotent stem cells.
    Kaye JA; Finkbeiner S
    Mol Cell Neurosci; 2013 Sep; 56():50-64. PubMed ID: 23459227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.
    Mattis VB; Tom C; Akimov S; Saeedian J; Østergaard ME; Southwell AL; Doty CN; Ornelas L; Sahabian A; Lenaeus L; Mandefro B; Sareen D; Arjomand J; Hayden MR; Ross CA; Svendsen CN
    Hum Mol Genet; 2015 Jun; 24(11):3257-71. PubMed ID: 25740845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.
    An MC; Zhang N; Scott G; Montoro D; Wittkop T; Mooney S; Melov S; Ellerby LM
    Cell Stem Cell; 2012 Aug; 11(2):253-63. PubMed ID: 22748967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic and transcriptional modulation of WDR5, a chromatin remodeling protein, in Huntington's disease human induced pluripotent stem cell (hiPSC) model.
    Baronchelli S; La Spada A; Ntai A; Barbieri A; Conforti P; Jotti GS; Redaelli S; Bentivegna A; De Blasio P; Biunno I
    Mol Cell Neurosci; 2017 Jul; 82():46-57. PubMed ID: 28476540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.
    Liu Y; Qiao F; Leiferman PC; Ross A; Schlenker EH; Wang H
    Hum Mol Genet; 2017 Nov; 26(22):4416-4428. PubMed ID: 28973411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity.
    Camnasio S; Delli Carri A; Lombardo A; Grad I; Mariotti C; Castucci A; Rozell B; Lo Riso P; Castiglioni V; Zuccato C; Rochon C; Takashima Y; Diaferia G; Biunno I; Gellera C; Jaconi M; Smith A; Hovatta O; Naldini L; Di Donato S; Feki A; Cattaneo E
    Neurobiol Dis; 2012 Apr; 46(1):41-51. PubMed ID: 22405424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells.
    Jeon I; Lee N; Li JY; Park IH; Park KS; Moon J; Shim SH; Choi C; Chang DJ; Kwon J; Oh SH; Shin DA; Kim HS; Do JT; Lee DR; Kim M; Kang KS; Daley GQ; Brundin P; Song J
    Stem Cells; 2012 Sep; 30(9):2054-62. PubMed ID: 22628015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway.
    Castiglioni V; Onorati M; Rochon C; Cattaneo E
    Neurobiol Dis; 2012 Apr; 46(1):30-40. PubMed ID: 22227000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Overview of the Use of iPSCs Huntington's Disease Modeling and Therapy.
    Csobonyeiova M; Polak S; Danisovic L
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32213859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons.
    Nekrasov ED; Vigont VA; Klyushnikov SA; Lebedeva OS; Vassina EM; Bogomazova AN; Chestkov IV; Semashko TA; Kiseleva E; Suldina LA; Bobrovsky PA; Zimina OA; Ryazantseva MA; Skopin AY; Illarioshkin SN; Kaznacheyeva EV; Lagarkova MA; Kiselev SL
    Mol Neurodegener; 2016 Apr; 11():27. PubMed ID: 27080129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iPSC-based drug screening for Huntington's disease.
    Zhang N; Bailus BJ; Ring KL; Ellerby LM
    Brain Res; 2016 May; 1638(Pt A):42-56. PubMed ID: 26428226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of human 3D striato-nigral assembloids to recapitulate medium spiny neuronal projection defects in Huntington's disease.
    Wu S; Hong Y; Chu C; Gan Y; Li X; Tao M; Wang D; Hu H; Zheng Z; Zhu Q; Han X; Zhu W; Xu M; Dong Y; Liu Y; Guo X
    Proc Natl Acad Sci U S A; 2024 May; 121(22):e2316176121. PubMed ID: 38771878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells.
    Xu X; Tay Y; Sim B; Yoon SI; Huang Y; Ooi J; Utami KH; Ziaei A; Ng B; Radulescu C; Low D; Ng AYJ; Loh M; Venkatesh B; Ginhoux F; Augustine GJ; Pouladi MA
    Stem Cell Reports; 2017 Mar; 8(3):619-633. PubMed ID: 28238795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Huntington's Disease iPSC-Derived Cortical Neurons Display Altered Transcriptomics, Morphology, and Maturation.
    Mehta SR; Tom CM; Wang Y; Bresee C; Rushton D; Mathkar PP; Tang J; Mattis VB
    Cell Rep; 2018 Oct; 25(4):1081-1096.e6. PubMed ID: 30355486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.